Literature DB >> 11106789

Endocannabinoids as cardiovascular modulators.

G Kunos1, Z Járai, S Bátkai, S K Goparaju, E J Ishac, J Liu, L Wang, J A Wagner.   

Abstract

Cannabinoids, the bioactive constituents of the marijuana plant and their synthetic and endogenous analogs cause not only neurobehavioral, but also cardiovascular effects. The most important component of these effects is a profound decrease in blood pressure and heart rate. Although multiple lines of evidence indicate that the hypotensive and bradycardic effects of anandamide and other cannabinoids are mediated by peripherally located CB1 cannabinoid receptors, anandamide can also elicit vasodilation in certain vascular beds, which is independent of CB1 or CB2 receptors. Possible cellular mechanisms underlying these effects and the cellular sources of vasoactive anandamide are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106789     DOI: 10.1016/s0009-3084(00)00194-8

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  38 in total

1.  Cannabinoids throw up a conundrum.

Authors:  DeWayne Townsend; Stanley A Thayer; David R Brown
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 2.  The complexities of the cardiovascular actions of cannabinoids.

Authors:  Michael D Randall; David A Kendall; Saoirse O'Sullivan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

3.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

4.  Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.

Authors:  Brian D Hudson; Terence E Hébert; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 6.  Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.

Authors:  Janos Paloczi; Zoltan V Varga; George Hasko; Pal Pacher
Journal:  Antioxid Redox Signal       Date:  2017-07-18       Impact factor: 8.401

7.  Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.

Authors:  L Moezi; S A Gaskari; H Liu; S K Baik; A R Dehpour; S S Lee
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

8.  CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes.

Authors:  Paola Nieri; Rosamiria Greco; Barbara Adinolfi; Maria Cristina Breschi; Enrica Martinotti; Carla Nannetti; Adriano Podestà
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-18       Impact factor: 3.000

9.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

10.  Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.

Authors:  E Herradón; M I Martín; V López-Miranda
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.